0001104659-20-133855.txt : 20201209 0001104659-20-133855.hdr.sgml : 20201209 20201209205357 ACCESSION NUMBER: 0001104659-20-133855 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201208 FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Jonathan CENTRAL INDEX KEY: 0001779805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 201379199 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 tm2038113-5_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2020-12-08 0 0001744659 Akero Therapeutics, Inc. AKRO 0001779805 Young Jonathan C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Operating Officer Common Stock 2020-06-30 5 A 0 E 1245 17.068 A 184845 D Common Stock 20000 I By EA Irrevocable Trust Common Stock 20000 I By CM Irrevocable Trust Common Stock 20000 I By JL Irrevocable Trust Stock Option (Right to Buy) 28.35 2020-12-08 4 A 0 77580 0 A 2030-12-07 Common Stock 77580 77580 D These shares were acquired on June 30, 2020 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2020. /s/ Jonathan Young 2020-12-09